Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17776425 | 0.90 | CNR1 (0.55) | HPGDKMT2ANPSR1CNR1 | |
| SCHEMBL18526676 | 0.90 | CNR1 (0.55) | HPGDKMT2ANPSR1CNR1 | |
| SCHEMBL3700677 | 0.90 | CNR1 (0.55) | HPGDKMT2ANPSR1CNR1 | |
| SCHEMBL26802536 | 0.88 | ALDH1A1 (0.54) | HPGDKMT2ANPSR1CNR1 | |
| SCHEMBL1072709 | 0.88 | ALDH1A1 (0.54) | HPGDKMT2ANPSR1CNR1 | |
| SCHEMBL25432324 | 0.86 | CNR1 (0.55) | CNR1 | |
| SCHEMBL22808475 | 0.83 | CNR1 (0.61) | MEN1KMT2AHSD17B10CNR1 | |
| SCHEMBL7131843 | 0.83 | CNR1 (0.61) | MEN1KMT2AHSD17B10CNR1 | |
| SCHEMBL6470529 | 0.82 | DPP4 (0.44) | — | |
| SCHEMBL13521122 | 0.80 | HPGD (0.51) | HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174015-B2 | Substituted heterocyclic derivative, preparation method and use thereof | XIAMEN UNIVERSITY (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20170334896-A1 | Substituted Heterocyclic Derivative, Preparation Method And Use Thereof | XIAMEN UNIVERSITY (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170029454-A1 | NKT CELL LIGANDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-02 | — | — | US | disclosed |
| EP-3049090-A1 | NKT CELL LIGANDS AND METHODS OF USE | The Scripps Research Institute (US) | 2016-08-03 | — | — | EP | disclosed |
| WO-2014210522-A1 | NKT CELL LIGANDS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334896-A1 | Substituted Heterocyclic Derivative, Preparation Method And Use Thereof | FAAH, NAAA, FAAH2 | PTGS2 1846/4885HPGD 71/4885MAPK1 2130/4885 |
| US-20170029454-A1 | NKT CELL LIGANDS AND METHODS OF USE | PBK, CD69, NFATC1 | PTGS2 1980/4885HPGD 1581/4885MAPK1 2533/4885 |
| US-10174015-B2 | Substituted heterocyclic derivative, preparation method and use thereof | DHPS, CYP3A5, CYP3A4 | PTGS2 886/4885HPGD 54/4885MAPK1 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.